Zofran MDL Plaintiffs Say ‘Clear Evidence’ Preemption Motion Is Premature
BOSTON — Plaintiffs in the Zofran birth defect multidistrict litigation on Jan. 5 opposed defendant GlaxoSmithKline LLC’s (GSK) motion to dismiss the entire litigation, saying that if there is any “clear...To view the full article, register now.
Already a subscriber? Click here to view full article